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This year we celebrate three years of publication of Stem
Cell Research & Therapy. In this short space of time, as
the number of journals in the stem cell and regenerative
medicine field has grown and continues to grow dramat-
ically, Stem Cell Research & Therapy has become
established as the destination for high quality open ac-
cess research into stem cell therapeutics.Why Stem Cell Research & Therapy?
When submitting work to a journal, authors understand-
ably wish to be assured of the journal’s quality. So what
makes Stem Cell Research & Therapy the leading forum
for translational stem cell research?Scope, indexing, and impact
Stem Cell Research & Therapy was launched in 2010
and was the first journal to focus on translational stem
cell research [1]. We also publish basic and clinical re-
search with a particular interest in the use of stem cells
for drug discovery and testing, stem cell manufacture,
and biomaterials. As discussed in last year’s editorial [2],
the journal was accepted for indexing in MEDLINE from
volume 1. The selection process for MEDLINE is similar
to the National Institutes of Health’s grant-making
process; journals are reviewed by a committee, and sci-
entific merit and quality of the editorial work are im-
portant considerations in this process [3], so authors can
be sure their article will be easily searchable via PubMed,
and that Stem Cell Research & Therapy has been recog-
nized as publishing content of suitable standard and
value to the community. Similarly, Stem Cell Research &
Therapy was accepted for tracking early by Thomson
Reuters and received its first partial Impact Factor
(of 3.21), an important metric in the research commu-
nity, in the 2011 Journal Citation Report.* Correspondence: editorial@stemcellres.com
1BioMed Central, Floor 6, 236 Gray’s Inn Road, London WC1X 8HB, UK
Full list of author information is available at the end of the article
© 2013 BioMed Central Ltd.A responsible and respected publisher
Since 2000, BioMed Central has been a pioneer of the
open access publishing model. A member of the Com-
mittee on Publication Ethics (COPE), BioMed Central
regularly reviews its editorial policies and processes to
ensure that they meet the highest standards [4]. All of
the research published in Stem Cell Research & Therapy
is thoroughly peer-reviewed and deposited in a number
of open access archives to ensure its continual availabil-
ity [5].
Our international, multidisciplinary Editorial Board
As well as assisting in the review of manuscripts, the
Stem Cell Research & Therapy Editorial Board offers in-
valuable guidance on the journal’s commissioned con-
tent and development. The Editorial Board members
reflect the diversity in the field, from basic scientists to
clinicians, including surgeons [6]. We aim to ensure that
the board reflects the international nature of the journal
and regularly review the contributions of its members to
ensure that the board remains engaged and active.
What are we publishing?
In 2012, we published 23 research articles, 23 reviews, 9
commentaries, and 2 editorials. By the end of March 2013,
we had already published 18 research articles, 8 reviews,
and 5 commentaries – submissions are also increasing, so
we expect that our publication numbers will continue to rise.
Our authors
Of the 23 research publications in 2012, 2 were from
Africa, 5 from Asia, 8 from Europe, and 8 from North
America. We are always looking for opportunities to pro-
mote the journal to an international audience and to
ensure that cost is never a barrier to publishing with us.
Who’s reading what
We are seeing strong increases in the number of article ac-
cesses; average monthly accesses exceeded 40,000 in the
first quarter of 2013. The majority of visitors to the website
are from the US, followed by China, the UK, and India,
then Japan, Germany, Canada, Italy, and Australia.
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Magali Cucchiarini and colleagues [7], who enhanced the
chondrogenic capacity of human mesenchymal stem cells
by SOX9 gene transfer; Nesrine Ben Azouna and col-
leagues [8], who replaced fetal bovine serum with human
platelet lysate for the culture of mesenchymal stem cells;
and Adetola Adesida and colleagues [9], who demon-
strated that isolating and expanding bone marrow mesen-
chymal stromal cells in hypoxic conditions increases their
chondrogenic potential.
The most-read reviews of the year were from Wesley
Jackson and colleagues [10], who used mesenchymal stem
cells to reduce scarring in wound healing, and Anish
Majumdar and colleagues [11], who reviewed the thera-
peutic potential of bone marrow stromal cells for cartilage
repair in osteoarthritis. The review by Majumdar and col-
leagues was published as part of the thematic series on
‘Clinical applications of stem cells’, edited by Mahendra
Rao, whose launch editorial on stem cells and regenerative
medicine was also popular [12].
What’s next?
This year will see the publication of the final articles in the
‘Clinical applications of stem cells’ series [13] and ‘Physical
influences on stem cells’ edited by Gordana Vunjak-
Novakovic [14]. The series on ‘Stem cell research in the
Asia-Pacific’, edited by Oscar Lee, Songtao Shi, Yufang Shi,
and Ying Jin, showcasing a selection of the innovative re-
search from this region [15], will also be completed.
Ronald Li, of the University of Hong Kong, will edit
our first thematic series for 2013, focusing on cardiovas-
cular regeneration. Further exciting series will soon be
announced, and research submissions are welcomed for
consideration alongside the commissioned review and
opinion pieces. We will also continue to publish individ-
ual reviews on topics of importance to the field, such as
upcoming articles from Luc Sensebé on producing mes-
enchymal stem cells according to Good Manufacturing
Practices and from Karin Tarte on the immunoregula-
tory properties of these cells.
We will continue to promote the quality content that
the journal publishes on its website, BioMed Central’s
Stem Cell gateway, and through blog posts and press re-
leases. The launch of the BioMed Central magazine,
Biome [16], also offers us a new venue to ensure that
our articles are brought to the attention of as wide an
audience as possible. As submissions increase, we will
be taking necessary steps to ensure that our authors
continue to benefit from our fair, fast, and thorough
peer-review process and expeditious publication. Our
aim is for all of our authors to continue to publish
with us in the future, like Bruce Bunnell, who has
published three research articles [17-19] in Stem Cell
Research & Therapy so far!What can we do for you?
We are very interested in hearing the views of the re-
search community we serve. Do you have any feedback
on your experience with the journal? Is there a topic you
would like to read about, an author you would like to
see featured, or a new article type you think we should
publish in Stem Cell Research & Therapy? Perhaps you
have a suggestion for a feature you would like to see on
the website or a way of making articles easier to read or
access. You are welcome to send comments and sugges-
tions via the editorial office or visit the BioMed Central
stand at one of the many conferences we exhibit at
throughout the year [20].
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